Almirall Licenses Aclidinium to Invida in Australia and New Zealand

BARCELONA, Spain & SINGAPORE--(BUSINESS WIRE)--Almirall (ALM:MC) and Invida Holdings Private Limited, a member of the Menarini Group, are pleased to announce that Almirall has granted Invida commercial rights for Aclidinium in Australia and New Zealand for the treatment of COPD. Financial details of the agreement have not been disclosed. The agreement includes both Aclidinium monotherapy and its combination with Formoterol. Invida, as a leading pharmaceutical commercialization company in Asia-Pacific, is committed to bringing innovative drugs and pharmaceutical research to doctors and patients in the region. Invida will be responsible for marketing the novel compound in Australia and New Zealand, both to primary and specialty care physicians.

Back to news